BACKGROUND AND PURPOSE:

• Aspirin reduces risk of major CV events by 19% and CV death by 9% in those with CVD
  • 5 to 10% of patients will still have recurrent CV events
• Eikelboom et al. (NEJM, 2017) assessed whether rivaroxaban, aspirin or both is most effective for secondary cardiovascular event prevention in those with stable atherosclerotic vascular disease

METHODS:

• Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
• 602 centers in 33 countries
• Double-blind randomized controlled (RCT) trial
• Inclusion criteria: Coronary artery disease, peripheral arterial disease, or both
• Participants were randomly assigned to 1 of 3 cohorts
  • rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily)
  • rivaroxaban (5 mg twice daily)
  • aspirin (100 mg once daily)
• Primary outcome
  • Composite of cardiovascular death, stroke, or myocardial infarction
• The study was stopped short at 23 month follow-up, due to superiority of the rivaroxaban and aspirin group

RESULTS:

• Comparing to aspirin-alone group, the rivaroxaban-plus-aspirin group had
  • Fewer patients (4.1% vs 5.4%) with adverse cardiovascular events (hazard ratio [HR] 0.76; 95% CI 0.66 – 0.86; P<0.001)
  • More major bleeding events occurred (3.1% vs 1.9% HR 1.70; 95% CI 1.40 to 2.05; P<0.001)
• Most major bleeding was into the gastrointestinal tract
• There was no significant difference in intracranial bleeding, fatal bleeding or bleeding into a critical organ
• There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group ([HR] 0.82; 95% CI 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025)
• When comparing rivaroxaban-alone group than in the aspirin-alone group, there was no significant difference in primary outcome but there were more major bleeding events

CONCLUSION:

• Rivaroxaban-plus-aspirin had better cardiovascular outcomes compared to aspirin alone
• Rivaroxaban alone did not impact outcomes

Learn More – Primary Sources:

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

Related ObG Topics:

Early-Onset Menopause – Increased Risk of Cardiovascular Disease?

Does Alcohol Consumption Increase or Decrease Mortality, CVD and Cancer Risk?  

PURE Study Results – Carbs vs Fat Intake to Reduce Cardiovascular Morbidity and Mortality?

More From the PURE Study: Does Type of Exercise Matter When it Comes to Decreasing Mortality and CVD?